Supernus Pharmaceuticals (SUPN)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 1 |
| Ownership rank: | 684 |
| % of all portfolios: | 0.01% |
| History | Portfolio Manager | Activity ▼ | Share change | % change to portfolio | |
| Q4 2023 | |||||
| ≡ | Third Avenue Management | Add 37.04% | 43,168 | 0.21 | |
| Q3 2023 | |||||
| ≡ | Third Avenue Management | Add 73.79% | 49,487 | 0.23 | |
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 7,409 | 0.00 | |
| Q2 2023 | |||||
| ≡ | Third Avenue Management | Add 2626.10% | 64,602 | 0.32 | |
| ≡ | Lee Ainslie - Maverick Capital | Reduce 11.86% | 997 | 0.00 | |
| Q1 2023 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 9.01% | 695 | 0.00 | |
| Q4 2022 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 13.22% | 1,175 | 0.00 | |
| Q3 2022 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 8,886 | 0.01 | |
| Q2 2022 | |||||
| ≡ | Third Avenue Management | Buy | 2,460 | 0.01 | |
| Q1 2022 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 4,000 | 0.00 | |
| Q4 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 90.47% | 37,962 | 0.00 | |
| Q3 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 26.71% | 15,289 | 0.00 | |
| Q2 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 57,251 | 0.02 | |
| Q1 2021 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 1,711 | 0.00 | |
| Q4 2020 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Reduce 97.41% | 64,466 | 0.00 | |
| Q3 2020 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 66,177 | 0.03 | |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.